Maria Paula Roberti

Maria Paula Roberti

Auto-generated profile, based on publicly available information

Maria Paula Roberti

Gustave Roussy Cancer Campus (GRCC), Villejuif, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MAMiles C. Andrews
Miles C. Andrews
CDConnie P. M. Duong
Connie P. M. Duong
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
Valerio IebbaValerio Iebba
Valerio Iebba
WCWei-Shen Chen
Wei-Shen Chen
JWJennifer A. Wargo
Jennifer A. Wargo

3 September 2019 in Cell Research
Verified
Journal Article
Open access
PDF file
NJNicolas Jacquelot
Nicolas Jacquelot
TYTakahiro Yamazaki
Takahiro Yamazaki
MRMaria P. Roberti
Maria P. Roberti
CDConnie P. M. Duong
Connie P. M. Duong
MAMiles C. Andrews
Miles C. Andrews
LZLaurence Zitvogel
Laurence Zitvogel
PD-1 blockade represents a major therapeutic avenue in anticancer immunotherapy. Delineating mechanisms of secondary resistance to this strategy is increasingly important. Here, we identified the deleterious role of signaling via the type I interferon (IFN) receptor in tumor and antigen presenting cells, that induced the expression of nitric oxide synthase 2 (NOS2), associated with intratumor accumulation of regulatory T cells (Treg) and myeloid cells and acquired resistance to anti-PD-1 monoclonal antibody (mAb). Sustained IFNβ transcription was observed in resistant tumors, in turn inducing PD-L1 and NOS2 expression in both tumor and dendritic cells (DC). Whereas PD-L1 was not involved in secondary resistance to anti-PD-1 mAb, pharmacological or genetic inhibition of NOS2 maintained long-term control of tumors by PD-1 blockade, through reduction of Treg and DC activation. Resistance to immunotherapies, including anti-PD-1 mAb in melanoma patients, was also correlated with the induction of a type I IFN signature. Hence, the role of type I IFN in response to PD-1 blockade should be revisited as sustained type I IFN signaling may contribute to resistance to therapy.

9 June 2023 in Science
Verified
Journal Article
Closed access
MFMarine Fidelle
Marine Fidelle
CRConrad Rauber
Conrad Rauber
CSCarolina Alves Costa Silva
Carolina Alves Costa Silva
ATAi-Ling Tian
Ai-Ling Tian
ILImran Lahmar
Imran Lahmar
LZLaurence Zitvogel
Laurence Zitvogel
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but the mechanisms underlying their immunosuppressive effects remain unknown. By inducing the down-regulation of mucosal addressin cell adhesion molecule 1 (MAdCAM-1) in the ileum, post-ABX gut recolonization by Enterocloster species drove the emigration of enterotropic α4β7 + CD4 + regulatory T 17 cells into the tumor. These deleterious ABX effects were mimicked by oral gavage of Enterocloster species, by genetic deficiency, or by antibody-mediated neutralization of MAdCAM-1 and its receptor, α4β7 integrin. By contrast, fecal microbiota transplantation or interleukin-17A neutralization prevented ABX-induced immunosuppression. In independent lung, kidney, and bladder cancer patient cohorts, low serum levels of soluble MAdCAM-1 had a negative prognostic impact. Thus, the MAdCAM-1–α4β7 axis constitutes an actionable gut immune checkpoint in cancer immunosurveillance.

25 May 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MRMaria Paula Roberti
Maria Paula Roberti
SYSatoru Yonekura
Satoru Yonekura
CDConnie P. M. Duong
Connie P. M. Duong
MPMarion Picard
Marion Picard
GFGladys Ferrere
Gladys Ferrere
LZLaurence Zitvogel
Laurence Zitvogel

1 January 2020 in OncoImmunology
Verified
Journal Article
Open access
RDRomain Daillère
Romain Daillère
BRBertrand Routy
Bertrand Routy
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
ACAlexandria Cogdill
Alexandria Cogdill
GFGladys Ferrere
Gladys Ferrere
LDLisa Derosa
Lisa Derosa
Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota composition that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. In this review, we explore preclinical and translational studies highlighting how eubiotic and dysbiotic microbiota composition can affect progression-free survival in cancer patients.

1 January 2020 in OncoImmunology
Verified
Journal Article
Open access
MRMaria Paula Roberti
Maria Paula Roberti
MPMarion Picard
Marion Picard
SYSatoru Yonekura
Satoru Yonekura
LZLaurence Zitvogel
Laurence Zitvogel
Why PD-1 blockade is ineffective in the vast majority of colorectal cancers (CCs) lacking microsatellite instability but harboring high densities of tumor infiltrating T cells and follicular T helper (TFH) and B cells remained so far an open conundrum. In a recent report published in Nature Medicine, we bring evidence in mice and patients that ileal microbiota turns tolerogenic apoptosis of ileal intestinal epithelial cells (IEC) into immunogenic cell demise capable of eliciting IL-1β-dependent TFH responses that benefit from anti-PD1 antibodies.